John F. DiPersio MD, PhD is the Golman Professor of Medicine and Director of The Center for Gene and Cellular Immunotherapy at the Washington University School of Medicine. His research has focused on targeting key elements of the hematopoietic niche for optimal stem cell mobilization and chemosensitization, mitigating GvHD in T cell replete transplants, understanding the genomic alterations in AML, and developing and testing in the clinic novel therapeutics and immuno-therapeutics, including cellular therapies, for the treatment of AML, ALL, T/B-NHL and multiple myeloma. Dr. DiPersio was instrumental in the development and FDA approval of Plerixafor, Motixafortide, and Ruxolitinib. He is the recipient of multiple awards and was past president of the ASTCT and member of the NCI Board of Scientific Counselors. He has authored or co-authored more than 490 publications, is a co-founder of two companies (WUGEN and Magenta) and holds multiple patents.